Identification of SR3335 (ML-176): a synthetic RORα selective inverse agonist
about
Orphan nuclear receptors and the regulation of nutrient metabolism: understanding obesityROR nuclear receptors: structures, related diseases, and drug discoveryThe therapeutic potential of RORγ modulators in the treatment of human diseaseCircadian molecular clock in lung pathophysiologyTherapeutic Effect of a Synthetic RORα/γ Agonist in an Animal Model of AutismClock genes, pancreatic function, and diabetesIdentification of Tetraazacyclic Compounds as Novel Potent Inhibitors Antagonizing RORγt Activity and Suppressing Th17 Cell DifferentiationRegulation of expression of citrate synthase by the retinoic acid receptor-related orphan receptor α (RORα)Regulation of p53 stability and apoptosis by a ROR agonistAction of RORs and their ligands in (patho)physiology.REV-ERB and ROR nuclear receptors as drug targets.Small molecule modifiers of circadian clocks.Small molecule amides as potent ROR-γ selective modulators.The identification of naturally occurring neoruscogenin as a bioavailable, potent, and high-affinity agonist of the nuclear receptor RORα (NR1F1).The REV-ERBs and RORs: molecular links between circadian rhythms and lipid homeostasis.Inhibition of RORγt activity and Th17 differentiation by a set of novel compounds.Antiobesity Effect of a Small Molecule Repressor of RORγ.Phosphoenolpyruvate Carboxykinase, a Key Enzyme That Controls Blood Glucose, Is a Target of Retinoic Acid Receptor-Related Orphan Receptor αIdentification of SR2211: a potent synthetic RORγ-selective modulator.Retinoic Acid-Related Orphan Receptors (RORs): Regulatory Functions in Immunity, Development, Circadian Rhythm, and Metabolism.RORα switches transcriptional mode of ERRγ that results in transcriptional repression of CYP2E1 under ethanol-exposure.Molecular Targets for Small-Molecule Modulators of Circadian Clocks.The mammalian clock and chronopharmacologyROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer.Metabolism of murine TH 17 cells: Impact on cell fate and functionCYP19A1, MIF and ABCA1 genes are targets of the RORα in monocyte and endothelial cells.Targeting hepatic glucose metabolism in the treatment of type 2 diabetes.Identification of New Nonsteroidal RORα Ligands; Related Structure-Activity Relationships and Docking Studies.RORα-dependent type 2 innate lymphoid cells are required and sufficient for mucous metaplasia in immature mice.Molecular mechanisms of transcriptional control by Rev-erbα: An energetic foundation for reconciling structure and binding with biological functionThe retinoid-related orphan receptor alpha is essential for the end-stage effector phase of experimental epidermolysis bullosa acquisita.Circadian factors BMAL1 and RORα control HIF-1α transcriptional activity in nucleus pulposus cells: implications in maintenance of intervertebral disc healthTopical ROR Inverse Agonists Suppress Inflammation in Mouse Models of Atopic Dermatitis and Acute Irritant Dermatitis.Altered Circadian Timing System-Mediated Non-Dipping Pattern of Blood Pressure and Associated Cardiovascular Disorders in Metabolic and Kidney Diseases.The nuclear retinoid-related orphan receptor-α regulates adipose tissue glyceroneogenesis in addition to hepatic gluconeogenesis.Development and Therapeutic Potential of Small-Molecule Modulators of Circadian Systems.The nuclear retinoid-related orphan receptor RORα controls circadian thermogenic programming in white fat depots.The role of RORα in salivary gland lesions in patients with primary Sjögren's syndrome
P2860
Q26823819-4F695CEC-97BD-4305-8D9C-CFB86A454002Q26861208-FA41E7C1-4A36-472F-B936-301D0D9364E6Q27022108-07BA77BA-B872-4557-9585-598DF61F5186Q28082902-4146785A-2D77-49CB-A2E4-0F2E5DBB5634Q28387385-1D498B50-B3E8-47FE-98CF-ECF0A79D66FFQ28393998-C6FACA5A-09B8-4E3C-9CA4-97FAA61023FEQ28547983-3E21E548-87A4-498E-A093-CA0F736A06FCQ34224788-1FF53161-623E-415B-B475-71E432B9D89CQ34235497-AD44C9AE-C375-4FBF-9562-90F0DD4C5EC4Q34287702-17BE6C4B-2924-4629-95C5-66BE0D0EBB49Q34407313-FFCB062A-4EA6-4F6D-849D-B22C5747AE92Q34480532-87747154-D916-4779-B20C-70248F360CEFQ34508948-52D1849A-D49D-40D6-A970-7A0C2F2FB05CQ34879391-8D0AAB87-A951-4BCD-B230-0B8BA95DA469Q35099319-7C8B1C5F-6E5C-4C65-9E19-5B9B7AAC1DD4Q35645390-176EAFF5-E499-43BD-A1E9-0F47198FFC7EQ35745907-2DF4794B-7493-402B-91AD-BA9A1AA6DC38Q35780366-F05968F0-C493-4758-8FAF-8D07E43140F3Q35903192-9A8B1263-69D0-4ECE-977E-82454E4E5591Q36571294-D2A147CF-4E9A-47FE-A268-89B1C6E12C3CQ36588873-BC51C1C8-7BAC-4D50-9F6C-8AD75D2DE161Q36779787-8ECA4F10-7AF7-4CEB-BBF4-359B61B9FE61Q36895254-8D383FCB-63F6-45CE-B800-14083C72C1C7Q37270422-63108DE9-7809-42AD-BF30-7255970307A8Q38439401-9C099CF5-29E5-4F02-9C54-66F1EF64D368Q38727292-A818458C-B5F9-4C4A-9711-86FA18A38692Q38925481-8743B6FC-8003-4049-A9BF-354FB0D1B74BQ39778851-E9117A3B-C841-4988-AB32-87AE7521E277Q40266176-4B981502-8E79-45BC-AD86-E0A23F7BA361Q40944335-2597E86E-A0A4-4F6A-AD0F-F8BC5E118625Q40962777-BA5A6D78-7E87-4451-BCC5-D0058A680674Q41133336-FF3F2B4E-7105-4ECC-BD95-AD8093919B7BQ47993781-97319220-8D8A-4534-953D-8A8A96EAABD8Q48132649-942EC5BE-0DC0-4CAA-960E-9B9D21992F5FQ51302292-7D8A4E1D-4B0E-430E-9997-D7CE4270DFDCQ51793703-0057725D-9F4D-4659-AA2F-E3ACDFBB860CQ52577553-8EFF6330-72C4-4AE4-B257-6C93AFD14A1BQ58761748-F8C7E9B0-1799-4B65-835B-9D9097D962C6
P2860
Identification of SR3335 (ML-176): a synthetic RORα selective inverse agonist
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Identification of SR3335 (ML-176): a synthetic RORα selective inverse agonist
@ast
Identification of SR3335 (ML-176): a synthetic RORα selective inverse agonist
@en
Identification of SR3335
@nl
type
label
Identification of SR3335 (ML-176): a synthetic RORα selective inverse agonist
@ast
Identification of SR3335 (ML-176): a synthetic RORα selective inverse agonist
@en
Identification of SR3335
@nl
prefLabel
Identification of SR3335 (ML-176): a synthetic RORα selective inverse agonist
@ast
Identification of SR3335 (ML-176): a synthetic RORα selective inverse agonist
@en
Identification of SR3335
@nl
P2093
P2860
P356
P1433
P1476
Identification of SR3335 (ML-176): a synthetic RORα selective inverse agonist
@en
P2093
Andrew A Butler
Derek R Duckett
Douglas J Kojetin
K Ganesh Kumar
Laura A Solt
Michael D Cameron
Naresh Kumar
Patrick R Griffin
Philippe Nuhant
William R Roush
P2860
P304
P356
10.1021/CB1002762
P50
P577
2010-12-06T00:00:00Z